Spatial redistribution of GFAP from astrocyte end-feet to soma — not upregulation — is the mechanistically relevant BBB-dysfunction event, detectable as altered plasma/CSF GFAP ratio and AQP4 depolarization before reactive gliosis onset.
Gut dysbiosis-driven butyrate deficit causes HDAC-mediated silencing of CLDN5 in brain endothelial cells; tributyrin prodrug restores CLDN5 expression via H3K27ac enrichment at the CLDN5 promoter, re-sealing the BBB in a virtuous cycle linking gut microbiome to neurovascular integrity.
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
Vascular Barrier Glymphatic
Convergent signals
No same-target convergence detected in this selection.
Divergent signals
No direct polarity conflicts detected among the selected hypotheses.
Verdict Summary
3/11
dimensions won
GFAP Perivascular Redistribution (End-Fe
7/11
dimensions won
Gut-BBB Axis: Tributyrin/Butyrate HDAC I
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.72
0.65
Evidence
0.18
0.74
Novelty
0.82
0.72
Feasibility
0.45
0.82
Impact
0.00
0.00
Druggability
0.52
0.78
Safety
0.68
0.72
Competition
0.70
0.60
Data
0.55
0.70
Reproducible
0.42
0.78
KG Connect
0.12
0.50
Score Breakdown
Dimension
GFAP Perivascular Redistributi
Gut-BBB Axis: Tributyrin/Butyr
Mechanistic
0.720
0.650
Evidence
0.180
0.740
Novelty
0.820
0.720
Feasibility
0.450
0.820
Impact
0.000
0.000
Druggability
0.520
0.780
Safety
0.680
0.720
Competition
0.700
0.600
Data
0.550
0.700
Reproducible
0.420
0.780
KG Connect
0.118
0.500
Evidence
GFAP Perivascular Redistribution (End-Feet Retraction) as Tr